CD8A and neoplasm: The collective clinical evidence to date suggests that ICIs are most effective in inflamed tumors as characterized by tumor PD-L1 expression, high CD8+ T cell density, or the presence of a strong IFN-γ cytolytic T cell signature [24–26].